PDF herunterladen
Planta Med 2012; 78(17): 1831-1836
DOI: 10.1055/s-0032-1315393
Pharmacokinetic Investigations
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in Rats

Karin G. Haug
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Benjamin Weber
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Guenther Hochhaus
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
,
Veronika Butterweck
1   Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA
2   Institute for Pharma Technology, School of Life Sciences, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 14. Juni 2012
revised 24. August 2012

accepted 28. August 2012

Publikationsdatum:
24. Oktober 2012 (online)

    Lizenzen und Reprints

Erratum zu diesem Artikel:

Pharmacokinetic Evaluation of Visnagin and Ammi visnaga Aqueous Extract after Oral Administration in RatsPlanta Med 2013; 79(03/04): 312-312
DOI: 10.1055/s-0032-1328273

Abstract

The furanochromone visnagin is one of the main compounds of Ammi visnaga L. (syn. Khella) with potential effects on kidney stone prevention. After determination of the pharmacokinetic properties of visnagin after intravenous bolus administration in rats, the aim of the present study was to evaluate the pharmacokinetic properties of visnagin and an aqueous Ammi visnaga extract after oral administration in rats. In two separate experiments, three doses of visnagin (2.5, 5, and 10 mg/kg) solubilized in 25 % Captisol® and three doses of Ammi visnaga extract (standardized on visnagin and containing equivalent amounts of visnagin) were administered by oral gavage to male Sprague-Dawley rats, respectively. Plasma samples were extracted and subsequently analyzed using a validated LC-MS/MS method. Plasma concentration-time profiles were explored by non-compartmental analysis. Visnagin plasma exposure (median AUClast and AUCinf) was significantly increased for all three doses (more than 10-fold for the low dose) when administered as an extract compared to the pure agent. For both the Ammi visnaga extract and the pure compound, AUClast and AUCinf increased disproportionately with an increase in dose. Visnagin resided significantly longer in the body when given in the form of AVE with up to a three times longer median MRTlast and MRTinf for the low dose. Cmax values after AVE administration were elevated and occurred at later time points in comparison to equivalent doses of pure visnagin. The terminal half-life increased with the dose for both AVE and pure visnagin, reaching a maximum value of 1.94 h for the 10 mg/kg pure compound group.

In conclusion, the exposure of visnagin is enhanced after extract administration and could result in a superior efficacy of AVE compared to an equivalent dose of visnagin.

Key words

Ammi visnaga - Apiaceae - visnagin - synergy - nonlinear pharmacokinetics - kidney stones
 

  • References

  • 1 Gunaydin K, Beyazit N. The chemical investigations on the ripe fruits of Ammi visnaga (Lam.) Lamarck growing in Turkey. Nat Prod Res 2004; 18: 169-175
    CrossrefPubMedGoogle Scholar
  • 2 Scales Jr. CD, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. Eur Urol 2012; 62: 160-165
    CrossrefPubMedGoogle Scholar
  • 3 Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63: 1817-1823
    CrossrefPubMedGoogle Scholar
  • 4 Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010; 12: e86-e96
    PubMedGoogle Scholar
  • 5 Chandhoke PS. Evaluation of the recurrent stone former. Urol Clin North Am 2007; 34: 315-322
    CrossrefPubMedGoogle Scholar
  • 6 Worcester EM, Coe FL. Nephrolithiasis. Prim Care 2008; 35: 369-391 vii
    CrossrefPubMedGoogle Scholar
  • 7 Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary?. Planta Med 2009; 75: 1095-1103
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Khan ZA, Assiri AM, Al-Afghani HM, Maghrabi TM. Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI-Khillah). Int Urol Nephrol 2001; 33: 605-608
    CrossrefPubMedGoogle Scholar
  • 9 Vanachayangkul P, Byer K, Khan S, Butterweck V. An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 2010; 17: 653-658
    CrossrefPubMedGoogle Scholar
  • 10 Vanachayangkul P, Chow N, Khan SR, Butterweck V. Prevention of renal crystal deposition by an extract of Ammi visnaga L. and its constituents khellin and visnagin in hyperoxaluric rats. Urol Res 2011; 39: 189-195
    CrossrefPubMedGoogle Scholar
  • 11 Haug KG, Weber B, Hochhaus G, Butterweck V. Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration. Eur J Pharm Sci 2012; 45: 79-89
    CrossrefPubMedGoogle Scholar
  • 12 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. Johnʼs Wort. J Nat Prod 2010; 73: 1015-1021
    CrossrefPubMedGoogle Scholar
  • 13 List PH, Schmid W, Weil E. Pure substance or galenic preparation? Attempt at a clarification on sample of Belladonna extract. Arzneimittelforschung 1969; 19: 181-185
    PubMedGoogle Scholar
  • 14 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64: 291-294
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Zeller W, Weber H, Panoussis B, Burge T, Bergmann R. Refinement of blood sampling from the sublingual vein of rats. Lab Anim 1998; 32: 369-376
    CrossrefPubMedGoogle Scholar
  • 16 Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd. edition. New York: Wiley & Sons; 1999: 106-125
    Google Scholar
  • 17 Gibaldi M, Perrier D. Pharmacokinetics. 2nd. edition. New York: Marcel Dekker, Inc.; 1982: 319-353
    Google Scholar
  • 18 Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci 1996; 85: 1142-1169
    CrossrefPubMedGoogle Scholar
  • 19 Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14: 556-567
    CrossrefPubMedGoogle Scholar
  • 20 Stella VJ, Rao VM, Zannou EA, Zia VV. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999; 36: 3-16
    CrossrefPubMedGoogle Scholar